TOP HEADLINES

Featured Story

  • Lilly divests U.S. animal health assets to Virbac ahead of Novartis deal

    French drugmaker Virbac said Monday it would pick up two products marketed by Novartis Animal Health in the U.S.--the parasiticides Sentinel Flavor Tabs and Sentinel Spectrum--which Eli Lilly has agreed to divest in advance of its acquisition of Novartis's animal products unit. Lilly reached the agreement with Virbac in connection with the U.S. Federal Trade Commission's review of its acquisition of Novartis Animal Health, according to a press release issued by Virbac.

Jaguar Animal Health trims IPO target number by 26%

Jaguar Animal Health, maker of gastrointestinal drugs for animals, is trimming its IPO target by 26% and hoping to raise as much as $51.75 million instead of the $70 million it was looking for when originally filing to go public back in August.

Analysts to Heska: Why has strong performance been overlooked?

Heska, a Colorado-based maker of veterinary diagnostics and specialty products, announced on Wednesday that its third-quarter earnings jumped 24% from the same period a year ago to $21.8 million, while its net income more than doubled to $513,000. Yet analysts were clearly impatient with the company's efforts to gain more visibility with both customers and investors.

Possible threat to strong launch of Merial's anti-flea pill NexGard adds to Sanofi's woes

Sanofi's animal health division, Merial, provided a rare bright spot in the company's third-quarter earnings report--but it wasn't quite bright enough to save CEO Chris Viehbacher's job. On Wednesday, just after announcing so-so earnings that triggered a massive selloff of Sanofi's stock, the company's board said it has "decided unanimously to remove" Viehbacher.

Zoetis forms European research pact to ID emerging animal diseases

Zoetis has embarked on a new mission to identify and quickly address diseases in livestock and companion animals by capitalizing on the latest advances in genetic sequencing and molecular biology. Towards that end, the company is teaming up with the Easter Bush Research Consortium--a group that includes several Scottish academic and scientific institutions--to form a new European research center headquartered in Edinburgh.

Lilly divests U.S. animal health assets to Virbac ahead of Novartis deal

French drugmaker Virbac said Monday it would pick up two products marketed by Novartis Animal Health in the U.S.--the parasiticides Sentinel Flavor Tabs and Sentinel Spectrum--which Eli Lilly has agreed to divest in advance of its acquisition of Novartis's animal products unit. Lilly reached the agreement with Virbac in connection with the U.S. Federal Trade Commission's review of its acquisition of Novartis Animal Health, according to a press release issued by Virbac.

MORE NEWS

From Our Sister Sites

FierceBiotech Research

U.K. researchers have hit upon a drug combination that appears to combat lung cancer by triggering self-destruction in tumor cells.

FierceDiagnostics

Amid efforts to counter the deadly Ebola outbreak, researchers and companies are homing in on rapid mobile tests as a more effective way to prevent the disease's spread.